Charles Schwab Investment Management Inc. Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Charles Schwab Investment Management Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,281,489 shares of the biopharmaceutical company's stock after buying an additional 87,482 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.58% of Gilead Sciences worth $589,873,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. OFI Invest Asset Management acquired a new stake in Gilead Sciences during the 3rd quarter valued at $26,000. Tompkins Financial Corp increased its position in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth about $29,000. Rakuten Securities Inc. acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $33,000. Finally, Financial Connections Group Inc. purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. HSBC raised shares of Gilead Sciences from a "reduce" rating to a "hold" rating and set a $69.00 price target for the company in a research report on Wednesday, April 24th. Wells Fargo & Company dropped their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an "equal weight" rating for the company in a research report on Monday, March 4th. Oppenheimer reaffirmed an "outperform" rating and set a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. Barclays lowered their price objective on Gilead Sciences from $80.00 to $76.00 and set an "equal weight" rating for the company in a report on Monday, April 29th. Finally, Maxim Group decreased their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a "buy" rating for the company in a report on Wednesday, May 1st. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Hold" and a consensus target price of $83.69.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $0.08 during trading on Tuesday, reaching $65.46. The company had a trading volume of 7,317,910 shares, compared to its average volume of 7,455,094. The firm's fifty day moving average is $70.25 and its 200 day moving average is $75.60. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The firm has a market capitalization of $81.50 billion, a PE ratio of 181.83, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a twelve month low of $64.33 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business had revenue of $6.69 billion during the quarter, compared to analysts' expectations of $6.36 billion. During the same quarter last year, the business posted $1.37 earnings per share. The company's quarterly revenue was up 5.3% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. Gilead Sciences's dividend payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.